BERWYN, Pa. (BUSINESS WIRE) #earnings Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its.
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
VRPX Intranasal Cannabidiol Product Candidate for Management of Epilepsy in Children and Adults BERWYN, Pa. (BUSINESS WIRE) #pharma Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress di.
Company Highlights Development Timelines for Product Candidates BERWYN, Pa. (BUSINESS WIRE) #earnings Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX) a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervou.
Virpax Successfully Completes Initial Preclinical Studies for VRP324 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.